Sharon X. Wen

Array ( [id] => 20393274 [patent_doc_number] => 20250368749 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-12-04 [patent_title] => COMPOSITIONS AND METHODS OF TREATING LUPUS NEPHRITIS [patent_app_type] => utility [patent_app_number] => 19/285781 [patent_app_country] => US [patent_app_date] => 2025-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31406 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19285781 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20232583 [patent_doc_number] => 20250289902 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-09-18 [patent_title] => REGIMENS AND METHODS OF TREATING MULTIPLE SCLEROSIS USING OFATUMUMAB [patent_app_type] => utility [patent_app_number] => 19/221422 [patent_app_country] => US [patent_app_date] => 2025-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2411 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19221422 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20206313 [patent_doc_number] => 20250276033 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-09-04 [patent_title] => COMPOSITIONS FOR IMPROVING KIDNEY FUNCTION IN PATIENTS WITH HEPATORENAL SYNDROME [patent_app_type] => utility [patent_app_number] => 19/213363 [patent_app_country] => US [patent_app_date] => 2025-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23381 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19213363 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20241012 [patent_doc_number] => 12421321 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-23 [patent_title] => Methods for treating fibrodysplasia ossificans progressiva [patent_app_type] => utility [patent_app_number] => 19/034098 [patent_app_country] => US [patent_app_date] => 2025-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 68679 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 223 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19034098 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20085126 [patent_doc_number] => 20250215062 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-03 [patent_title] => POLYPEPTIDE ANTIGEN OF BOVINE AND SHEEP PREGNANCY-ASSOCIATED GLYCOPROTEIN AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 19/000524 [patent_app_country] => US [patent_app_date] => 2024-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 0 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19000524 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20007512 [patent_doc_number] => 20250145734 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-08 [patent_title] => HUMANIZED ANTIBODIES AGAINST IRHOM2 [patent_app_type] => utility [patent_app_number] => 18/988307 [patent_app_country] => US [patent_app_date] => 2024-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24257 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18988307 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19931752 [patent_doc_number] => 12304949 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-20 [patent_title] => Anti-S100A4 humanized antibodies, uses and methods [patent_app_type] => utility [patent_app_number] => 18/962263 [patent_app_country] => US [patent_app_date] => 2024-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 9414 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18962263 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19785587 [patent_doc_number] => 20250059266 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-20 [patent_title] => ANTIBODIES FOR TREATING ALPHA-SYNUCLEINOPATHIES [patent_app_type] => utility [patent_app_number] => 18/938970 [patent_app_country] => US [patent_app_date] => 2024-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15336 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18938970 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20006012 [patent_doc_number] => 20250144234 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-08 [patent_title] => RNA for In vivo Transfection with Increased Expression [patent_app_type] => utility [patent_app_number] => 18/934237 [patent_app_country] => US [patent_app_date] => 2024-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 69402 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 128 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18934237 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19998497 [patent_doc_number] => 20250136719 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-01 [patent_title] => HEPARANASE-NEUTRALIZING A54 MONOCLONAL ANTIBODY [patent_app_type] => utility [patent_app_number] => 18/895539 [patent_app_country] => US [patent_app_date] => 2024-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12707 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18895539 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19692871 [patent_doc_number] => 20250011416 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-09 [patent_title] => METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE [patent_app_type] => utility [patent_app_number] => 18/888316 [patent_app_country] => US [patent_app_date] => 2024-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12946 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18888316 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19464209 [patent_doc_number] => 20240317878 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => REGIMENS AND METHODS OF TREATING MULTIPLE SCLEROSIS USING OFATUMUMAB [patent_app_type] => utility [patent_app_number] => 18/597624 [patent_app_country] => US [patent_app_date] => 2024-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8343 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18597624 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19380965 [patent_doc_number] => 20240270835 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => BINDING AGENTS [patent_app_type] => utility [patent_app_number] => 18/442575 [patent_app_country] => US [patent_app_date] => 2024-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38613 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -51 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18442575 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19430953 [patent_doc_number] => 20240299451 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => TARGETING B CELL ACTIVATING FACTOR RECEPTOR (BAFF-R) USING LIGAND-BASED CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELLS [patent_app_type] => utility [patent_app_number] => 18/441467 [patent_app_country] => US [patent_app_date] => 2024-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7715 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18441467 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19447353 [patent_doc_number] => 20240307483 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => COMPOSITIONS FOR IMPROVING KIDNEY FUNCTION IN PATIENTS WITH HEPATORENAL SYNDROME [patent_app_type] => utility [patent_app_number] => 18/416231 [patent_app_country] => US [patent_app_date] => 2024-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27770 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18416231 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19359366 [patent_doc_number] => 20240261400 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-08 [patent_title] => METHODS FOR REDUCING OR ELIMINATING THE NEED FOR LIPOPROTEIN APHERESIS IN PATIENTS WITH HYPERLIPIDEMIA BY ADMINISTERING ALIROCUMAB [patent_app_type] => utility [patent_app_number] => 18/407331 [patent_app_country] => US [patent_app_date] => 2024-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21724 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18407331 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19112854 [patent_doc_number] => 20240124604 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => ANTI-PSGL-1 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/396607 [patent_app_country] => US [patent_app_date] => 2023-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21239 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18396607 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19112865 [patent_doc_number] => 20240124615 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => BISPECIFIC ANTIBODIES AND USES OF THE SAME THEREOF [patent_app_type] => utility [patent_app_number] => 18/389819 [patent_app_country] => US [patent_app_date] => 2023-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12628 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18389819 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19510592 [patent_doc_number] => 20240342278 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-17 [patent_title] => ANTIBODIES SPECIFICALLY BINDING TO MASP-3 FOR THE TREATMENT OF VARIOUS DISEASES AND DISORDERS [patent_app_type] => utility [patent_app_number] => 18/523203 [patent_app_country] => US [patent_app_date] => 2023-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 103417 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18523203 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19491648 [patent_doc_number] => 12110344 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-08 [patent_title] => Antibodies that bind to cis and uses thereof [patent_app_type] => utility [patent_app_number] => 18/515714 [patent_app_country] => US [patent_app_date] => 2023-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 15 [patent_no_of_words] => 135483 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 122 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18515714 [rel_patent_id] =>[rel_patent_doc_number] =>)